Literature DB >> 18945969

Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD.

Andrew J Mhyre1, A Mario Marcondes, Emily Y Spaulding, H Joachim Deeg.   

Abstract

The role of the marrow microenvironment in the pathophysiology of myelodysplastic syndromes (MDSs) remains controversial. Using stromal/hematopoietic cell cocultures, we investigated the effects of stroma-derived signals on apoptosis sensitivity in hematopoietic precursors. The leukemia-derived cell line KG1a is resistant to proapoptotic ligands. However, when cocultured with the human stromal cell line HS5 (derived from normal marrow) and exposed to tumor necrosis factor-alpha (TNF-alpha), KG1a cells showed caspase-3 activation and induction of apoptosis. Apoptosis was contact dependent. Identical results were obtained in coculture with primary stroma. Gene-expression profiling of KG1a cells identified coculture-induced up-regulation of various genes involved in apoptosis, including PYCARD. Suppression of PYCARD expression in KG1a by miRNA interfered with apoptosis. Knockdown of the TNF receptor 1 (TNFR1) or TNFR2 in HS5 cells had no effect. However, knockdown of R1 in KG1a cells prevented TNF-alpha-induced apoptosis, while apoptosis was still induced by TNF-alpha-related apoptosis-inducing ligand. Primary CD34(+) cells from MDS marrow, when cocultured with HS5 and TNF-alpha, also underwent apoptosis. In contrast, no apoptosis was observed in CD34(+) cells from the marrow of healthy donors. These data indicate that stroma may convey not only protective effects on hematopoietic cells, but, dependent upon the milieu, may also facilitate apoptosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18945969      PMCID: PMC2628371          DOI: 10.1182/blood-2008-04-152686

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.

Authors:  Matvey Lukashev; Doreen LePage; Cheryl Wilson; Véronique Bailly; Ellen Garber; Alex Lukashin; Apinya Ngam-ek; Weike Zeng; Norman Allaire; Steve Perrin; Xianghong Xu; Kendall Szeliga; Kathleen Wortham; Rebecca Kelly; Cindy Bottiglio; Jane Ding; Linda Griffith; Glenna Heaney; Erika Silverio; William Yang; Matt Jarpe; Stephen Fawell; Mitchell Reff; Amie Carmillo; Konrad Miatkowski; Joseph Amatucci; Thomas Crowell; Holly Prentice; Werner Meier; Shelia M Violette; Fabienne Mackay; Dajun Yang; Robert Hoffman; Jeffrey L Browning
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

2.  Proliferation response of leukemic cells to CD70 ligation oscillates with recurrent remission and relapse in a low-grade lymphoma.

Authors:  Yael Kaufmann; Ninette Amariglio; Esther Rosenthal; Yasmine Jacob Hirsch; Amira Many; Gideon Rechavi
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

Review 3.  Immunomodulation in myelodysplastic syndromes.

Authors:  Mikkael A Sekeres; Alan List
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

4.  Mechanism of ASC-mediated apoptosis: bid-dependent apoptosis in type II cells.

Authors:  M Hasegawa; K Kawase; N Inohara; R Imamura; W-C Yeh; T Kinoshita; T Suda
Journal:  Oncogene       Date:  2006-09-11       Impact factor: 9.867

5.  Cutting edge: ASC mediates the induction of multiple cytokines by Porphyromonas gingivalis via caspase-1-dependent and -independent pathways.

Authors:  Debra J Taxman; Jinghua Zhang; Catherine Champagne; Daniel T Bergstralh; Heather A Iocca; John D Lich; Jenny Pan-Yun Ting
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

6.  Dual role of TMS1/ASC in death receptor signaling.

Authors:  M J Parsons; P M Vertino
Journal:  Oncogene       Date:  2006-05-22       Impact factor: 9.867

7.  NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs).

Authors:  Daniella M B Kerbauy; Vladimir Lesnikov; Nissa Abbasi; Sudeshna Seal; Bart Scott; H Joachim Deeg
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

8.  Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines.

Authors:  Shao Xu Ying; Sudeshna Seal; Nissa Abbassi; David M Hockenbery; Hans-Peter Kiem; Xiao Li; John M Pagel; Ajay K Gopal; H J Deeg
Journal:  Leuk Lymphoma       Date:  2007-05

9.  Proteinase 3 is an IL-32 binding protein.

Authors:  Daniela Novick; Menachem Rubinstein; Tania Azam; Aharon Rabinkov; Charles A Dinarello; Soo-Hyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-17       Impact factor: 11.205

10.  Distinct roles of TLR2 and the adaptor ASC in IL-1beta/IL-18 secretion in response to Listeria monocytogenes.

Authors:  Nesrin Ozören; Junya Masumoto; Luigi Franchi; Thirumala-Devi Kanneganti; Mathilde Body-Malapel; Ilkim Ertürk; Rajesh Jagirdar; Li Zhu; Naohiro Inohara; John Bertin; Anthony Coyle; Ethan P Grant; Gabriel Núñez
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

View more
  21 in total

1.  Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.

Authors:  Ruben A Ferrer; Manja Wobus; Catrin List; Rebekka Wehner; Claudia Schönefeldt; Barbara Brocard; Brigitte Mohr; Martina Rauner; Marc Schmitz; Maik Stiehler; Gerhard Ehninger; Lorenz C Hofbauer; Martin Bornhäuser; Uwe Platzbecker
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

2.  Quantitative analysis of glycans, related genes, and proteins in two human bone marrow stromal cell lines using an integrated strategy.

Authors:  Xiang Li; Dongliang Li; Xingchen Pang; Ganglong Yang; H Joachim Deeg; Feng Guan
Journal:  Exp Hematol       Date:  2015-05-01       Impact factor: 3.084

Review 3.  Murine xenogeneic models of myelodysplastic syndrome: an essential role for stroma cells.

Authors:  Xiang Li; H Joachim Deeg
Journal:  Exp Hematol       Date:  2013-10-11       Impact factor: 3.084

4.  Aryl hydrocarbon receptor-dependent apoptotic cell death induced by the flavonoid chrysin in human colorectal cancer cells.

Authors:  Sean M Ronnekleiv-Kelly; Manabu Nukaya; Carol J Díaz-Díaz; Bryant W Megna; Patrick R Carney; Peter G Geiger; Gregory D Kennedy
Journal:  Cancer Lett       Date:  2015-10-26       Impact factor: 8.679

5.  The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes.

Authors:  Xiang Li; A Mario Marcondes; Theodore A Gooley; H Joachim Deeg
Journal:  Blood       Date:  2010-06-18       Impact factor: 22.113

6.  BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

Authors:  Aldo M Roccaro; Antonio Sacco; Patricia Maiso; Abdel Kareem Azab; Yu-Tzu Tai; Michaela Reagan; Feda Azab; Ludmila M Flores; Federico Campigotto; Edie Weller; Kenneth C Anderson; David T Scadden; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

7.  TNF receptor 2, not TNF receptor 1, enhances mesenchymal stem cell-mediated cardiac protection following acute ischemia.

Authors:  Megan L Kelly; Meijing Wang; Paul R Crisostomo; Aaron M Abarbanell; Jeremy L Herrmann; Brent R Weil; Daniel R Meldrum
Journal:  Shock       Date:  2010-06       Impact factor: 3.454

8.  Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes.

Authors:  Xiang Li; Feng Xu; ChunKang Chang; John Byon; Thalia Papayannopoulou; H Joachim Deeg; A Mario Marcondes
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

9.  Identification of DJ-1/PARK-7 as a determinant of stroma-dependent and TNF-alpha-induced apoptosis in MDS using mass spectrometry and phosphopeptide analysis.

Authors:  A Mario Marcondes; Xiang Li; Ted A Gooley; Brian Milless; H Joachim Deeg
Journal:  Blood       Date:  2010-01-08       Impact factor: 22.113

10.  Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.

Authors:  Yuqi Jing; Valery Chavez; Yuguang Ban; Nicolas Acquavella; Doraya El-Ashry; Alexey Pronin; Xi Chen; Jaime R Merchan
Journal:  Mol Cancer Res       Date:  2017-07-05       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.